loading
Adaptimmune Therapeutics Plc Adr stock is traded at $0.1882, with a volume of 49.92M. It is down -14.45% in the last 24 hours and up +270.67% over the past month. Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
See More
Previous Close:
$0.2201
Open:
$0.205
24h Volume:
49.92M
Relative Volume:
0.58
Market Cap:
$49.59M
Revenue:
$175.04M
Net Income/Loss:
$-44.52M
P/E Ratio:
-1.0456
EPS:
-0.18
Net Cash Flow:
$-56.05M
1W Performance:
+22.67%
1M Performance:
+270.67%
6M Performance:
-12.42%
1Y Performance:
-78.58%
1-Day Range:
Value
$0.178
$0.214
1-Week Range:
Value
$0.1309
$0.275
52-Week Range:
Value
$0.0403
$0.9116

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name
Name
Adaptimmune Therapeutics Plc Adr
Name
Phone
44 1235 430000
Name
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Name
Employee
506
Name
Twitter
@Adaptimmune
Name
Next Earnings Date
2025-08-08
Name
Latest SEC Filings
Name
ADAP's Discussions on Twitter

Compare ADAP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ADAP
Adaptimmune Therapeutics Plc Adr
0.1871 58.34M 175.04M -44.52M -56.05M -0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.94 106.37B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.86 59.90B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.00 60.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
797.24 49.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
322.93 36.88B 4.56B -176.77M 225.30M -1.7177

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-29-25 Downgrade H.C. Wainwright Buy → Neutral
Jun-26-25 Downgrade Mizuho Outperform → Neutral
Jul-30-24 Initiated H.C. Wainwright Buy
May-30-24 Initiated Scotiabank Sector Outperform
Mar-24-23 Initiated Bryan Garnier Buy
Jan-03-23 Upgrade Guggenheim Neutral → Buy
Nov-09-22 Upgrade Mizuho Neutral → Buy
May-28-21 Initiated Barclays Underweight
Apr-22-20 Initiated Mizuho Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-31-19 Initiated ROTH Capital Buy
May-30-19 Resumed Citigroup Buy
May-07-19 Downgrade SVB Leerink Outperform → Mkt Perform
Mar-17-17 Initiated Wells Fargo Market Perform
Oct-24-16 Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16 Initiated Raymond James Outperform
Feb-25-16 Initiated Citigroup Buy
Jun-01-15 Initiated BofA/Merrill Neutral
Jun-01-15 Initiated Guggenheim Buy
Jun-01-15 Initiated Leerink Partners Outperform
View All

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News

pulisher
Oct 09, 2025

Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews

Oct 09, 2025
pulisher
Oct 09, 2025

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech

Oct 09, 2025
pulisher
Oct 08, 2025

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech

Oct 08, 2025
pulisher
Oct 06, 2025

Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews

Oct 06, 2025
pulisher
Sep 26, 2025

Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews

Sep 26, 2025
pulisher
Sep 25, 2025

Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews

Sep 25, 2025
pulisher
Sep 19, 2025

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance

Sep 19, 2025
pulisher
Sep 18, 2025

Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance

Sep 18, 2025
pulisher
Sep 18, 2025

Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance

Sep 18, 2025
pulisher
Sep 18, 2025

Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance

Sep 18, 2025
pulisher
Sep 17, 2025

Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance

Sep 17, 2025
pulisher
Sep 14, 2025

What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance

Sep 14, 2025
pulisher
Sep 12, 2025

Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance

Sep 12, 2025
pulisher
Sep 11, 2025

The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance

Sep 11, 2025
pulisher
Sep 10, 2025

Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com

Sep 10, 2025
pulisher
Sep 10, 2025

What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com

Sep 10, 2025
pulisher
Sep 06, 2025

Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance

Sep 06, 2025
pulisher
Sep 05, 2025

Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance

Sep 05, 2025
pulisher
Sep 03, 2025

Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com

Sep 03, 2025
pulisher
Aug 29, 2025

Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance

Aug 29, 2025
pulisher
Aug 21, 2025

Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com

Aug 21, 2025
pulisher
Aug 20, 2025

Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.

Aug 20, 2025
pulisher
Aug 19, 2025

Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com

Aug 19, 2025
pulisher
Aug 18, 2025

Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance

Aug 18, 2025
pulisher
Aug 14, 2025

Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN

Aug 14, 2025
pulisher
Aug 13, 2025

Adaptimmune Sales Jump 59 Percent - sharewise.com

Aug 13, 2025
pulisher
Aug 12, 2025

Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance

Aug 12, 2025
pulisher
Aug 11, 2025

ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Aug 11, 2025
pulisher
Aug 06, 2025

HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance

Aug 06, 2025
pulisher
Aug 05, 2025

Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint

Aug 05, 2025
pulisher
Aug 04, 2025

Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com

Aug 04, 2025
pulisher
Jul 31, 2025

Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com India

Jul 31, 2025
pulisher
Jul 29, 2025

Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa

Jul 29, 2025
pulisher
Jul 28, 2025

Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India

Jul 28, 2025
pulisher
Jul 28, 2025

Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com

Jul 28, 2025
pulisher
Jul 24, 2025

XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance

Jul 24, 2025
pulisher
Jul 21, 2025

Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance

Jul 21, 2025
pulisher
Jun 25, 2025

Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com

Jun 25, 2025
pulisher
Jun 17, 2025

Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX

Jun 17, 2025
pulisher
Jun 12, 2025

Best Momentum Stocks to Buy for June 12th - Yahoo Finance

Jun 12, 2025
pulisher
May 30, 2025

Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

Context Therapeutics names new CMO to advance T cell therapies - Investing.com

May 29, 2025
pulisher
May 22, 2025

KANZHUN LIMITED Sponsored ADR (BZ) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance

May 22, 2025
pulisher
May 13, 2025

Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK

May 13, 2025
pulisher
May 13, 2025

Healthy Upside Potential: Merus N.V (MRUS) - Sete News

May 13, 2025
pulisher
May 12, 2025

How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com

May 12, 2025
pulisher
May 07, 2025

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

All Markets & Instruments Available to Trade - Capital.com

May 06, 2025
pulisher
May 03, 2025

Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister

May 03, 2025
pulisher
May 01, 2025

Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News

May 01, 2025

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.74
price down icon 3.91%
$83.20
price down icon 1.84%
$31.81
price down icon 0.22%
$102.97
price down icon 1.44%
$162.62
price down icon 1.13%
biotechnology ONC
$323.10
price down icon 3.93%
Cap:     |  Volume (24h):